Table 1. Oral status of the experimental groups at different periods of analysis.
| Clinical Condition | Occurrence of radiotherapy side effects N (%) | ||||
|---|---|---|---|---|---|
| Before RT1 | After RT2 | 30 d after RT3 | 6 months after RT4 | ||
| Mucositis | |||||
| Group I | 0 (0.0) | 12 (92.31) | 8 (61.54) | 4 (40.0) | |
| Group II | 0 (0.0) | 10 (90.91) | 7 (63.63) | 3 (33.33) | |
| Group III | 0 (0.0) | 11 (78.57) | 8 (66.67) | 4 (36.36) | |
| Group IV | 0 (0.0) | 10 (83.33) | 8 (72.73) | 7 (77.78) | |
| Dermatitis | |||||
| Group I | 0 (0.0) | 12 (92.31) | 8 (61.54) | 1 (10.0) | |
| Group II | 0 (0.0) | 11 (100.0) | 8 (88.89) | 2 (22.22) | |
| Group III | 0 (0.0) | 11 (78.57) | 7 (63.64) | 0 (0.0) | |
| Group IV | 1 (6.67) | 12 (100.0) | 7 (77.78) | 2 (22.22) | |
| Candidosis | |||||
| Group I | 0 (0.0) | 3 (23.08) | 1 (7.69) | 0 (0.0) | |
| Group II | 0 (0.0) | 3 (27.27) | 2 (18.18) | 1 (9.09) | |
| Group III | 0 (0.0) | 4 (28.57) | 1 (8.33) | 0 (0.0) | |
| Group IV | 1 (6.67) | 8 (66.67) | 5 (45.45) | 3 (33.33) | |
| Xerostomia | |||||
| Group I | 0 (0.0) | 12 (92.31) | 10 (76.92) | 8 (80.0) | |
| Group II | 1 (6.67) | 11 (100.0) | 10 (90.91) | 6 (75.0) | |
| Group III | 0 (0.0) | 12 (85.71) | 9 (75.0) | 7 (63.63) | |
| Group IV | 1 (6.67) | 11 (91.67) | 8 (72.73) | 7 (77.78) | |
1
Number of patients in the different groups just before radiotherapy: Group I, N= 15; Group II, N= 15; Group III, N= 15; Group IV, N= 15. Total = 60.
2
Number of patients in the different groups immediately after radiotherapy: Group I, N= 13; Group II, N= 11; Group III, N= 14; Group IV, N= 12. Total = 50.
3
Number of patients in the different groups 30 days after conclusion of radiotherapy: Group I, N= 13; Group II, N= 11; Group III, N= 12; Group IV, N= 11. Total= 47.
4
Number of patients in the different groups 6 months after conclusion of radiotherapy: Group I, N= 10; Group II, N= 9; Group III, N= 11; Group IV, N= 9. Total= 39.